Your browser doesn't support javascript.
loading
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Daver, N; Kantarjian, H; Ravandi, F; Estey, E; Wang, X; Garcia-Manero, G; Jabbour, E; Konopleva, M; O'Brien, S; Verstovsek, S; Kadia, T; Dinardo, C; Pierce, S; Huang, X; Pemmaraju, N; Diaz-Pines-Mateo, M; Cortes, J; Borthakur, G.
Afiliação
  • Daver N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kantarjian H; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Estey E; Division of Hematology, University of Washington School of Medicine, Seattle, WA, USA.
  • Wang X; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jabbour E; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Konopleva M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • O'Brien S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Verstovsek S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kadia T; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dinardo C; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pierce S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Huang X; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pemmaraju N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Diaz-Pines-Mateo M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cortes J; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Borthakur G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leukemia ; 30(2): 268-73, 2016 Feb.
Article em En | MEDLINE | ID: mdl-26365212
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Aminoglicosídeos Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Aminoglicosídeos Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos